TY  - JOUR
AB  - Introduction: Pulmonary drug delivery is a complex field of research combining physics which drive aerosol transport and deposition and biology which underpins efficacy and toxicity of inhaled drugs. A myriad of preclinical methods, ranging from in-silico to in-vitro, ex-vivo and in-vivo, can be implemented.Areas covered: The present review covers in-silico mathematical and computational fluid dynamics modelization of aerosol deposition, cascade impactor technology to estimated drug delivery and deposition, advanced in-vitro cell culture methods and associated aerosol exposure, lung-on-chip technology, ex-vivo modeling, in-vivo inhaled drug delivery, lung imaging, and longitudinal pharmacokinetic analysis.Expert opinion: No single preclinical model can be advocated; all methods are fundamentally complementary and should be implemented based on benefits and drawbacks to answer specific scientific questions. The overall best scientific strategy depends, among others, on the product under investigations, inhalation device design, disease of interest, clinical patient population, previous knowledge. Preclinical testing is not to be separated from clinical evaluation, as small proof-of-concept clinical studies or conversely large-scale clinical big data may inform preclinical testing. The extend of expertise required for such translational research is unlikely to be found in one single laboratory calling for the setup of multinational large-scale research consortiums.
AU  - Ehrmann, S.*
AU  - Schmid, O.
AU  - Darquenne, C.*
AU  - Rothen-Rutishauser, B.*
AU  - Sznitman, J.*
AU  - Yang, L.
AU  - Barosova, H.*
AU  - Vecellio, L.*
AU  - Mitchell, J.*
AU  - Henze-Vourc´h, N.*
C1  - 58207
C2  - 48313
CY  - 2-4 Park Square, Milton Park, Abingdon Or14 4rn, Oxon, England
SP  - 463-478
TI  - Innovative preclinical models for pulmonary drug delivery research.
JO  - Expert Opin. Drug Deliv.
VL  - 17
IS  - 4
PB  - Taylor & Francis Ltd
PY  - 2020
SN  - 1742-5247
ER  - 

TY  - JOUR
AB  - There is a high incidence of nasal disorders including chronic rhinosinusitis (CRS), affecting ∼ 14% of the total population. However, a topical treatment regimen shows only modest efficacy, and drug delivery to the posterior nose, osteomeatal area, and paranasal sinuses is still a challenge. Therefore, the primary treatment option of CRS is functional endonasal sinus surgery (FESS). Most nasally administered aerosolized drugs are efficiently filtered by the nasal valve and do not reach the sinuses, the site of chronic inflammation. Sinus ventilation, nasal and paranasal aerosol deposition can be achieved by using a pulsating airflow, offering new topical treatment options for nasal disorders. Inhalation studies in nasal casts and in healthy volunteers have shown up to 8% of the nasally deposited drug within the sinuses, which could not be achieved using nasal pump sprays. In addition, compared with nasal pump sprays, retention kinetics of the radiolabel deposit in the nose was prolonged by about a factor of five. With this efficiency, topical aerosol therapies of sinus disorders can be achieved and, owing to the prolonged retention, reduced application modes are possible. This offers new treatment options of sinus-nasal disorders in comparison with or after FESS.
AU  - Möller, W.
AU  - Münzing, W.*
AU  - Canis, M.*
C1  - 5656
C2  - 27735
SP  - 1239-1245
TI  - Clinical potential of pulsating aerosol for sinus drug delivery.
JO  - Expert Opin. Drug Deliv.
VL  - 7
IS  - 11
PB  - Informa Healthcare USA, Inc.
PY  - 2010
SN  - 1742-5247
ER  -